Mean Platelet Volume and Lipid Profile Levels In Patients With Follicular Thyroid Cancer

Öz

Background: In this study, we studied plasma mean platelet volume (MPV) and lipid profile levels in the follicular thyroid cancer patients and the correlation in between these parameters. Methods: The levels of MPV and lipid profile tests were assessed in 52 patients with follicular thyroid cancer and 33 control subjects. Results: While serum MPV levels were low in the healthy control group, this value was significantly increased in follicular thyroid cancer patients (FTC) (p = 0.001). In addition, when serum total cholesterol (TC), triglyceride (TG) and C-reactive protein (CRP) levels in the healthy control group were compared with FTC patients, it was found that these three values increased statistically significantly (p = 0.001) in these patients. Finally, when the healthy control group and FTC groups were compared for low-density lipoprotein cholesterol (LDL-C) and high-density lipoprotein cholesterol (HDL-C) levels; HDL-C values were lower in the FTC groups (p=0.002) while LDL-C values were measured statistically significantly higher (p = 0.001). There was a positive correlation between serum MPV levels and total cholesterol, LDL-C and TG levels (r=0.532, p = 0.001; r=0.701, p = 0.001; r=0.724, p = 0.001, respectively). However, when serum MPV levels and HDL-C levels were compared in terms of correlation, no correlation was detected between them. Finally, a correlation was also determined between measured tumor dimensions, total cholesterol, LDL-C and TG levels (r=0.756, p = 0.001; r=0.493, p = 0.001; r=0.527, p = 0.001, respectively). No statistically significant correlation was observed between MPV and tumor size (r = 0.239, p = 0.088) Conclusions: The results of the present study demonstrated that the patients with FTC are affected to increased serum MPV and changed lipid profile values which contribute to increased risk factor of cardiovascular diseases.

Anahtar Kelimeler

• Mean platelet volume
• Cholesterol
• Triglyceride
• Cancer

Folikuler tiroid kanserli hastalarda ortalama trombosit volumu ve lipid profili

Öz

Giriş: Bu çalışmada, foliküler tiroid kanseri hastalarında plazma ortalama trombosit hacmi (MPV) ve lipit profili düzeyleri ve bu parametreler arasındaki korelasyonu araştırıldı. Yöntem: Foliküler tiroid kanseri olan 52 hasta ve 33 kontrol grubunda MPV düzeyleri ve lipit profili testleri değerlendirildi. Bulgular: Sağlıklı kontrol grubunda serum MPV düzeyleri düşük iken, bu değer foliküler tiroid kanseri (FTC) hastalarında anlamlı olarak artmıştı (p = 0,001). Ayrıca, sağlıklı kontrol grubundaki serum toplam kolesterol (TC), trigliserid (TG) ve C-reaktif protein (CRP) düzeyleri FTC hastalarıyla karşılaştırıldığında, bu üç değerin söz konusu hastalarda istatistiksel olarak anlamlı bir şekilde (p = 0,001) arttığı saptanmıştır. Son olarak, sağlıklı kontrol grubu ile FTC grupları arasında düşük yoğunluklu lipoprotein kolesterol (LDL-C) ve yüksek yoğunluklu lipoprotein kolesterol (HDL-C) düzeyleri karşılaştırıldığında; HDL-C değerleri FTC gruplarında daha düşük (p = 0,002) iken, LDL-C değerleri istatistiksel olarak anlamlı derecede daha yüksek (p = 0,001) ölçülmüştür. Serum MPV düzeyleri ile toplam kolesterol, LDL-C ve TG düzeyleri arasında pozitif bir korelasyon saptandı (sırasıyla r=0,532, p = 0,001; r=0,701, p = 0,001; r=0,724, p = 0,001). Ancak, serum MPV düzeyleri ile HDL-C düzeyleri korelasyon açısından karşılaştırıldığında, aralarında herhangi bir korelasyon saptanmamıştır. Son olarak, ölçülen tümör boyutları ile toplam kolesterol, LDL-C ve TG düzeyleri arasında da bir korelasyon saptanmıştır (sırasıyla r=0,756, p = 0,001; r=0,493, p = 0,001; r=0,527, p = 0,001). MPV ile tümör boyutu arasında istatistiksel olarak anlamlı bir korelasyon gözlenmemiştir (r = 0,239, p = 0,088) Sonuçlar: Bu çalışmanın sonuçları, FTC hastalarının, kardiyovasküler hastalık risk faktörlerinin artmasına katkıda bulunan yüksek serum MPV ve değişmiş lipit profili değerlerinden etkilendiğini göstermiştir.

Anahtar Kelimeler

• Ortalama trombosit hacmi
• Kolesterol
• Trigliserid
• Kanser

Kaynakça

1. Biondi, B., & Wartofsky, L. (2014). Treatment with thyroid hormone. Endocrine Reviews, 35(3), 433–512. https://doi.org/10.1210/er.2013-1083
2. Cabanillas, M. E., Patel, A., Danysh, B. P., Dadu, R., Kopetz, S., & Falchook, G. (2015). BRAF inhibitors: Experience in thyroid cancer and general review of toxicity. Hormones and Cancer, 6(1), 21–36. https://doi.org/10.1007/s12672-014-0207-9
3. Cetin, B., Kosova, F., Akinci, M., Atalay, C., Seki, A., Uyar, O., & Ari, Z. (2014). Peroxidation products and antioxidant enzyme activities in multinodular goiter and papillary thyroid cancer patients. Journal of Clinical & Experimental Oncology, 3(3), 2014–2018. https://doi.org/10.4172/2324-9110.1000127
4. Chen, X., Iqbal, N., & Boden, G. (1999). The effects of free fatty acids on gluconeogenesis and glycogenolysis in normal subjects. The Journal of Clinical Investigation, 103(3), 365–372. https://doi.org/10.1172/JCI5479
5. Cohen, J. C., Horton, J. D., & Hobbs, H. H. (2011). Human fatty liver disease: Old questions and new insights. Science, 332(6037), 1519–1523. https://doi.org/10.1126/science.1204265
6. Cohen, Y., Xing, M., Mambo, E., Guo, Z., Wu, G., Trink, B., Beller, U., Westra, W. H., Ladenson, P. W., & Sidransky, D. (2003). BRAF mutation in papillary thyroid carcinoma. Journal of the National Cancer Institute, 95(8), 625–627. https://doi.org/10.1093/jnci/95.8.625
7. DeFilippis, R. A., Chang, H., Dumont, N., Rabban, J. T., Chen, Y.-Y., Fontenay, G. V., Berman, H. K., Gauthier, M. L., Zhao, J., Hu, D., Marx, J. J., Tjoe, J. A., Ziv, E., Febbraio, M., Kerlikowske, K., Parvin, B., & Tlsty, T. D. (2012). CD36 repression activates a multicellular stromal program shared by high mammographic density and tumor tissues. Cancer Discovery, 2(9), 826–839. https://doi.org/10.1158/2159-8290.CD-12-0107
8. Fagin, J., & Nikiforov, Y. (2000). Molecular genetics of tumors of thyroid follicular cells. The Thyroid, 8, 886–898.

9. Gasparyan, A. Y., Ayvazyan, L., Mikhailidis, D. P., & Kitas, G. D. (2011). Mean platelet volume: A link between thrombosis and inflammation? Current Pharmaceutical Design, 17(1), 47–58. https://doi.org/10.2174/138161211795049804
10. Glatz, J. F., & Luiken, J. J. (2017). From fat to FAT (CD36/SR-B2): Understanding the regulation of cellular fatty acid uptake. Biochimie, 136, 21–26. https://doi.org/10.1016/j.biochi.2016.12.007
11. Li, B. R., Xia, L. Q., Liu, J., Zhang, Y., Deng, M., Zhong, H. J., Feng, T.T., He, P.P., & Ouyang, X. P. (2017). miR-758-5p regulates cholesterol uptake via targeting the CD36 3'UTR. Biochemical and Biophysical Research Communications, 494(1–2), 384–389. https://doi.org/10.1016/j.bbrc.2017.09.150
12. Magen, E., Mishal, J., Zeldin, Y., Feldman, V., Kidon, M., Schlesinger, M., & Sthoeger, Z. (2010). Increased mean platelet volume and C-reactive protein levels in patients with chronic urticaria with a positive autologous serum skin test. The American Journal of the Medical Sciences, 339(6), 504–508. https://doi.org/10.1097/maj.0b013e3181db6ed5
13. Nieman, K. M., Kenny, H. A., Penicka, C. V., Ladanyi, A., Buell-Gutbrod, R., Zillhardt, M. R., Romero, I. L., Carey, M. S., Mills, G. B., Hotamisligil, G. S., Yamada, S. D., Peter, M. E., Gwin, K., & Lengyel, E. (2011). Adipocytes promote ovarian cancer metastasis and provide energy for rapid tumor growth. Nature Medicine, 17(11), 1498–1503. https://doi.org/10.1038/nm.2492
14. Pascual, G., Avgustinova, A., Mejetta, S., Martín, M., Castellanos, A., Attolini, C. S. O., Berenguer, A., Prats, N., Toll, A., Hueto, J. A., Bescós, C., Di Croce, L., & Benitah, S. A. (2017). Targeting metastasis-initiating cells through the fatty acid receptor CD36. Nature, 541(7635), 41–45. https://doi.org/10.1038/nature20791
15. Pellegriti, G., Frasca, F., Regalbuto, C., Squatrito, S., & Vigneri, R. (2013). Worldwide increasing incidence of thyroid cancer: Update on epidemiology and risk factors. Journal of Cancer Epidemiology, 2013, 965212. https://doi.org/10.1155/2013/965212
16. Röhrig, F., & Schulze, A. (2016). The multifaceted roles of fatty acid synthesis in cancer. Nature Reviews Cancer, 16(11), 732–749. https://doi.org/10.1038/nrc.2016.89
17. Sanchez-Vega, F., Mina, M., Armenia, J., Chatila, W. K., Luna, A., La, K. C., Dimitriadoy, S., Liu, D. L., Kantheti, H. S., Saghafinia, S., Chakravarty, D., Daian, F., Gao, Q., Bailey, M. H., Liang, W.-W., Foltz, S. M., Shmulevich, I., Ding, L., Heins, Z., Ochoa, A., Gross, B., Gao, J., Zhang, H., Kundra, R., Kandoth, C., Bahceci, I., Dervishi, L., Dogrusoz, U., Zhou, W., Shen, H., Laird, P. W., Way, G. P., Greene, C. S., Liang, H., Xiao, Y., Wang, C., Iavarone, A., Berger, A. H., Bivona, T. G., Lazar, A. J., Hammer, G. D., Giordano, T., Kwong, L. N., McArthur, G., Huang, C., Tward, A. D., Frederick, M. J., McCormick, F., Meyerson, M., Cancer Genome Atlas Research Network, Van Allen, E. M., Cherniack, A. D., Ciriello, G., Sander, C., & Schultz, N. (2018). Oncogenic signaling pathways in The Cancer Genome Atlas. Cell, 173(2), 321–337. https://doi.org/10.1016/j.cell.2018.03.035
18. Sandhaus, L. M., & Meyer, P. (2002). How useful are CBC and reticulocyte reports to clinicians. American Journal of Clinical Pathology, 118(5), 787–793. https://doi.org/10.1309/cqgg-hy0u-lrkl-glmp
19. Sherman, S. I. (2003). Thyroid carcinoma. Lancet, 361(9356), 501–511. https://doi.org/10.1016/S0140-6736(03)12488-9
20. Tandon, N. N., Kralisz, U., & Jamieson, G. A. (1989). Identification of glycoprotein IV (CD36) as a primary receptor for platelet-collagen adhesion. Journal of Biological Chemistry, 264(13), 7576–7583.
21. Yoshida, H., & Granger, D. N. (2009). Inflammatory bowel disease: A paradigm for the link between coagulation and inflammation. Inflammatory Bowel Diseases, 15(8), 1245–1255. https://doi.org/10.1002/ibd.20896